Recent Nutraceutical Interventions for Hypertension: A Comprehensive Review of Randomized Clinical Evidence

Read the full article here

Tweets with this article

Joel Kahn MD, FACC

When combined with other lifestyle interventions, nutraceuticals could present a holistic approach to reducing cardiovascular risks, enhancing the quality of life for hypertensive patients globally.

Coronary Artery Calcium and cardiovascular risk factors analysis after Radiotherapy for breast cancer

Read the full article here

john doe 5 July 5, 2025

The Implications of Alpha-Gal Syndrome for Dental and Medical Treatment

Read the full article here

john doe 5 July 4, 2025

150 minutes of exercise per week could help reverse prediabetes

Read the full article here

john doe 5 July 4, 2025

Factors influencing health-promoting lifestyles in patients after percutaneous coronary intervention: A cross-sectional study

Read the full article here

john doe 5 July 4, 2025

Poor lifestyle habits nearly double your chance of developing AFib

Read the full article here

john doe 5 July 4, 2025

Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer

Read the full article here

john doe 5 July 3, 2025

Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603)

Read the full article here

john doe 5 July 3, 2025

Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with previously untreated clear cell renal cell carcinoma (ccRCC): Results from an expansion cohort of the phase 1b STELLAR-002 study

Read the full article here

john doe 5 July 3, 2025

Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma

Read the full article here

john doe 5 July 3, 2025

Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA

Read the full article here

john doe 5 July 3, 2025

Related Articles